Results of a study presented at the annual meeting of the American Society of Clinical Oncology in Chicago indicates that an experimental drug combination could be effective against HER-2-positive breast cancer. The new therapy, called trastuzumab emtansine (T-DM1), combines a monoclonal antibody with a potent chemotherapy agent. The combination is exciting because Herceptin guides the cell-killing chemotherapy agent to HER-2 receptors on breast cancer cells. This focused attack targets cancer cells and largely bypasses healthy cells, which the chemotherapy drug would otherwise damage. In the study, which included nearly 1,000 women with HER-2-positive breast cancer that had spread either within the breast or elsewhere in the body, 65.4% of the women taking T-DM1 were still alive after two year, compared to 47.5% of those on standard treatment for this type of cancer. In addition, women on T-DM1 experienced far fewer side effects.
Breast cancer isn’t just a woman’s disease. Men can get it, too—about 1% of breast cancer is diagnosed in men. Since few men know that, they often fail to recognize its earliest signs and end up seeing a doctor later in the process than women do. The result: Men face treatment for larger and more advanced tumors, and their cancer is more likely to have spread to other parts of the body. The largest study to date on outcomes in men with breast cancer indicates that the five-year survival rate for women with breast cancer was 83%, compared to 74% for men. Even men diagnosed with early stage breast cancer still fared worse than women, although the gap closed for men and women diagnosed with later-stage disease. Since breast cancer in men isn’t often on doctors’ radar screens, men should be aware and check themselves.
The FDA today revoked its 2008 approval of the drug Avastin to treat breast cancer, concluding that the drug does little to help women with breast cancer while putting them at risk for potentially life-threatening side effects. Avastin will remain on the market (and so be potentially available to women with breast cancer) because it has also been approved to treat other types of cancer.
A 28-year study of 106,000 women found that moderate alcohol slightly increases a woman’s risk of developing breast cancer. Women who had the equivalent of three to six drinks a week had a modest increase in their risk of breast cancer (15%) compared to women who never drank alcohol. That would translate into an extra 3 cases of breast cancer per 1,000 women per year. The risks were the same for wine, beer, and spirits. Because moderate drinking appears to prevent some types of heart disease—which affects more women than breast cancer does—it’s important for women to think about alcohol in light of their own personal health situation.
New government statistics show that there are nearly 12 million cancer survivors in the United States. In many ways this is terrific news, and a testament to improved diagnosis and treatment options. But there’s a flip side to surviving cancer, and many survivors are never totally “free” of the disease. The ongoing psychological and emotional issues can be almost as much a challenge as cancer treatment was. Harvard Health editor Ann MacDonald explores the ongoing fear of recurrence, survivor guilt, the “Damocles syndrome,” and more.
Health problems, or treatments for them, sometimes thwart sexual desire and sexual function. There may not be a quick fix for health-related sexual problems, but there are things you can do to enjoy your love life while taking care of the rest of your health.